Insider Buying: Vivani Medical (NASDAQ:VANI) Director Acquires 1,737,765 Shares of Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired 1,737,765 shares of Vivani Medical stock in a transaction dated Thursday, January 15th. The shares were bought at an average price of $1.14 per share, with a total value of $1,981,052.10. Following the transaction, the director directly owned 26,564,109 shares in the company, valued at approximately $30,283,084.26. The trade was a 7.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gregg Williams also recently made the following trade(s):

• On Monday, December 15th, Gregg Williams acquired 1,737,765 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.14 per share, for a total transaction of $1,981,052.10.
• On Saturday, November 15th, Gregg Williams bought 1,737,764 shares of Vivani Medical stock. The shares were purchased at an average price of $1.14 per share, for a total transaction of $1,981,050.96.
• On Monday, October 27th, Gregg Williams bought 3,703,703 shares of Vivani Medical stock. The stock was purchased at an average cost of $1.62 per share, with a total value of $5,999,998.86.

Vivani Medical Trading Up 5.6%

Shares of Vivani Medical stock traded up $0.07 during trading on Tuesday, reaching $1.34. The company’s stock had a trading volume of 255,642 shares, compared to its average volume of 102,939. The firm has a market cap of $97.83 million, a PE ratio of -2.97 and a beta of 3.07. Vivani Medical, Inc. has a fifty-two week low of $0.91 and a fifty-two week high of $1.92. The company has a 50-day moving average price of $1.35 and a two-hundred day moving average price of $1.39.

Vivani Medical (NASDAQ:VANI) last announced its earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. On average, analysts predict that Vivani Medical, Inc. will post -0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, January 9th. Zacks Research upgraded shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 12th. Finally, Wall Street Zen raised Vivani Medical to a “sell” rating in a research note on Saturday, November 22nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $4.00.

Institutional Investors Weigh In On Vivani Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP increased its position in Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares in the last quarter. Panagora Asset Management Inc. acquired a new position in shares of Vivani Medical during the second quarter worth $25,000. Finally, Citadel Advisors LLC purchased a new position in shares of Vivani Medical in the third quarter valued at $26,000. 6.78% of the stock is currently owned by institutional investors and hedge funds.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.